

Marc Buyse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10738596/publications.pdf>

Version: 2024-02-01

161
papers

26,709
citations

11608

70
h-index

7136

153
g-index

170
all docs

170
docs citations

170
times ranked

23419
citing authors

#	ARTICLE	IF	CITATIONS
1	FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 229-237.	0.8	2,718
2	Adjuvant Trastuzumab in HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 1273-1283.	13.9	2,254
3	Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 262-272.	3.0	1,824
4	Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1183-1192.	3.0	1,128
5	Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series. <i>Clinical Cancer Research</i> , 2007, 13, 3207-3214.	3.2	839
6	OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 394-400.	0.8	750
7	Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. <i>Clinical Cancer Research</i> , 2008, 14, 5158-5165.	3.2	745
8	Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor—Positive Breast Carcinomas Through Genomic Grade. <i>Journal of Clinical Oncology</i> , 2007, 25, 1239-1246.	0.8	711
9	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1729.	3.8	711
10	The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer. <i>New England Journal of Medicine</i> , 1995, 332, 629-634.	13.9	706
11	Preoperative Radiotherapy as Adjuvant Treatment in Rectal Cancer. <i>Annals of Surgery</i> , 1988, 208, 606-614.	2.1	617
12	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 8664-8670.	0.8	607
13	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 872-877.	0.8	539
14	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2—Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGIC—A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 443-451.	0.8	490
15	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	5.1	451
16	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 367-377.	5.1	444
17	Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. <i>Lancet</i> , The, 2000, 356, 373-378.	6.3	395
18	Criteria for the Validation of Surrogate Endpoints in Randomized Experiments. <i>Biometrics</i> , 1998, 54, 1014.	0.8	364

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	0.8	343
20	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3097-3104.	0.8	327
21	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5218-5224.	0.8	321
22	Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1987-1992.	0.8	314
23	Adjuvant Therapy of Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 1988, 259, 3571.	3.8	296
24	Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials. <i>Journal of the National Cancer Institute</i> , 2007, 99, 998-1003.	3.0	291
25	Biomarkers and surrogate end points—the challenge of statistical validation. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 309-317.	12.5	283
26	Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 2896-2903.	0.8	256
27	Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 540-551.	4.3	222
28	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4569-4574.	0.8	220
29	Alteration of Topoisomerase II α Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 859-867.	0.8	192
30	Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1980-1986.	0.8	189
31	Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2013, 31, 3764-3775.	0.8	185
32	Common pitfalls in statistical analysis: Clinical versus statistical significance. <i>Perspectives in Clinical Research</i> , 2015, 6, 169.	0.5	172
33	Multifactorial Approach to Predicting Resistance to Anthracyclines. <i>Journal of Clinical Oncology</i> , 2011, 29, 1578-1586.	0.8	169
34	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2011, 12, 1134-1142.	5.1	165
35	Validation of surrogate end points in multiple randomized clinical trials with failure time end points. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2001, 50, 405-422.	0.5	163
36	Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. <i>Pharmaceutical Statistics</i> , 2006, 5, 173-186.	0.7	150

#	ARTICLE	IF	CITATIONS
37	Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1958-1962.	0.8	148
38	Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. <i>Statistics in Medicine</i> , 2010, 29, 3245-3257.	0.8	147
39	The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. , 1999, 18, 3435-3451.		145
40	Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 121-133.	3.0	140
41	Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. <i>Lancet Oncology</i> , The, 2009, 10, 341-350.	5.1	138
42	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013, 49, 1565-1577.	1.3	136
43	Phase III Study Comparing a Semimonthly With a Monthly Regimen of Fluorouracil and Leucovorin As Adjuvant Treatment for Stage II and III Colon Cancer Patients: Final Results of GERCOR C96.1. <i>Journal of Clinical Oncology</i> , 2007, 25, 3732-3738.	0.8	135
44	Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2 "Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3877-3884.	0.8	135
45	Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2004, 22, 484-492.	0.8	133
46	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1600-1607.	3.0	133
47	Ensuring trial validity by data quality assurance and diversification of monitoring methods. <i>Clinical Trials</i> , 2008, 5, 49-55.	0.7	129
48	Integrating biomarkers in clinical trials. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 171-182.	1.5	124
49	Comparison of prognostic gene expression signatures for breast cancer. <i>BMC Genomics</i> , 2008, 9, 394.	1.2	123
50	Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3224-3229.	0.8	121
51	Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. <i>BMJ</i> , The, 2013, 346, f457-f457.	3.0	119
52	Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 141-148.	0.8	113
53	HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 3518-3528.	0.8	113
54	ON THE RELATIONSHIP BETWEEN RESPONSE TO TREATMENT AND SURVIVAL TIME. , 1996, 15, 2797-2812.		110

#	ARTICLE	IF	CITATIONS
55	Statistical challenges in the evaluation of surrogate endpoints in randomized trials. <i>Contemporary Clinical Trials</i> , 2002, 23, 607-625.	2.0	108
56	Analysis of Fcγ ₃ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3478-3486.	3.2	106
57	Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 886-893.	5.1	104
58	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. <i>Value in Health</i> , 2017, 20, 487-495.	0.1	101
59	Cell kinetic indicators of premalignant stages of colorectal cancer. <i>Cancer</i> , 1985, 56, 124-129.	2.0	99
60	Interim analysis of a phase III study on preoperative radiation therapy in resectable rectal carcinoma. Trial of the gastrointestinal tract cancer cooperative group of the European organization for research on treatment of cancer (EORTC). <i>Cancer</i> , 1985, 55, 2373-2379.	2.0	97
61	Data fraud in clinical trials. <i>Clinical Investigation</i> , 2015, 5, 161-173.	0.0	94
62	Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. <i>Biometrical Journal</i> , 2016, 58, 104-132.	0.6	93
63	Current Issues in Adjuvant Treatment of Stage II Colon Cancer. <i>Annals of Surgical Oncology</i> , 2006, 13, 887-898.	0.7	89
64	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 87-96.	3.0	89
65	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	0.8	87
66	Meta-Analyses Based on Abstracted Data: A Step in the Right Direction, but Only a First Step. <i>Journal of Clinical Oncology</i> , 2004, 22, 3839-3841.	0.8	85
67	Fraud in Medical Research. <i>Contemporary Clinical Trials</i> , 2000, 21, 415-427.	2.0	84
68	A statistical approach to central monitoring of data quality in clinical trials. <i>Clinical Trials</i> , 2012, 9, 705-713.	0.7	83
69	Should Dukes' B patients receive adjuvant therapy? A statistical perspective. <i>Seminars in Oncology</i> , 2001, 28, 20-24.	0.8	82
70	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1667-1670.	3.0	78
71	Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. <i>Journal of Rheumatology</i> , 2007, 34, 607-15.	1.0	78
72	Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). <i>Breast Cancer Research and Treatment</i> , 2013, 138, 99-108.	1.1	76

#	ARTICLE	IF	CITATIONS
73	Overall Survival Is Not a Realistic End Point for Clinical Trials of New Drugs in Advanced Solid Tumors: A Critical Assessment Based on Recently Reported Phase III Trials in Colorectal and Breast Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2045-2047.	0.8	69
74	The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2004, 167, 103-124.	0.6	69
75	VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 312-324.	0.2	69
76	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. <i>Journal of Clinical Oncology</i> , 2010, 28, 460-465.	0.8	67
77	End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal. <i>Journal of Clinical Oncology</i> , 2007, 25, 3572-3575.	0.8	66
78	Individual- and trial-level surrogacy in colorectal cancer. <i>Statistical Methods in Medical Research</i> , 2008, 17, 467-475.	0.7	65
79	Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1750-1754.	0.8	63
80	Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1205-1212.	1.1	60
81	Precision medicine needs randomized clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 317-323.	12.5	60
82	Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 361-370.	5.1	59
83	Outcome measures in multimodal rectal cancer trials. <i>Lancet Oncology</i> , The, 2020, 21, e252-e264.	5.1	56
84	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , 2015, 107, djv261.	3.0	53
85	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. <i>Breast Cancer Research</i> , 2012, 14, R70.	2.2	52
86	A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz002.	1.4	52
87	A unifying approach for surrogate marker validation based on Prentice's criteria. <i>Statistics in Medicine</i> , 2006, 25, 205-221.	0.8	51
88	Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy "An Aide et Recherche en Cancérologie Digestive Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4199-4204.	0.8	51
89	A perspective on surrogate endpoints in controlled clinical trials. <i>Statistical Methods in Medical Research</i> , 2004, 13, 177-206.	0.7	49
90	Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 833-842.	2.4	48

#	ARTICLE	IF	CITATIONS
91	Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes. <i>Biometrical Journal</i> , 2002, 44, 921-935.	0.6	44
92	Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. <i>BMJ Open</i> , 2013, 3, e001802.	0.8	43
93	An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1230-1239.	0.7	43
94	Simplified hierarchical linear models for the evaluation of surrogate endpoints. <i>Journal of Statistical Computation and Simulation</i> , 2003, 73, 643-658.	0.7	40
95	Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 232-240.	3.0	40
96	Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 421-425.	1.0	38
97	<i>HER2</i> Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 228-238.	1.9	38
98	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	0.8	37
99	Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. <i>Haematologica</i> , 2011, 96, 1106-1112.	1.7	33
100	Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies. <i>Journal of Clinical Oncology</i> , 2011, 29, 4719-4720.	0.8	33
101	Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. <i>Drugs</i> , 2017, 77, 713-719.	4.9	33
102	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 516-516.	21.5	32
103	Exploring and validating surrogate endpoints in colorectal cancer. <i>Lifetime Data Analysis</i> , 2008, 14, 54-64.	0.4	30
104	Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy. <i>Oncologist</i> , 2022, 27, 266-271.	1.9	29
105	Interim analyses, stopping rules and data monitoring in clinical trials in europe. <i>Statistics in Medicine</i> , 1993, 12, 509-520.	0.8	28
106	Reformulating the hazard ratio to enhance communication with clinical investigators. <i>Clinical Trials</i> , 2008, 5, 641-642.	0.7	26
107	The trials of Dr. Bernard Fisher: A European perspective on an American episode. <i>Contemporary Clinical Trials</i> , 1997, 18, 1-13.	2.0	25
108	Non-inferiority trials in breast and non-small cell lung cancer: Choice of non-inferiority margins and other statistical aspects. <i>Acta Oncologica</i> , 2012, 51, 890-896.	0.8	25

#	ARTICLE	IF	CITATIONS
109	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. <i>Computational Statistics and Data Analysis</i> , 2011, 55, 2748-2757.	0.7	23
110	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 82953-82960.	0.8	22
111	Issues of efficiency in combining proportions of deaths from several clinical trials. <i>Statistics in Medicine</i> , 1987, 6, 565-576.	0.8	21
112	Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e66848.	1.1	21
113	Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments. <i>Current Opinion in Oncology</i> , 2008, 20, 466-471.	1.1	20
114	Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial. <i>Gastric Cancer</i> , 2016, 19, 24-30.	2.7	20
115	Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , 2017, 38, 1632-1637.	1.0	19
116	Common pitfalls in statistical analysis: "P" values, statistical significance and confidence intervals. <i>Perspectives in Clinical Research</i> , 2015, 6, 116.	0.5	18
117	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	2.2	17
118	Challenges in breast cancer clinical trial design in the postgenomic era. <i>Current Opinion in Oncology</i> , 2004, 16, 536-541.	1.1	16
119	Towards validation of statistically reliable biomarkers. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 89-95.	2.2	16
120	Omics-based clinical trial designs. <i>Current Opinion in Oncology</i> , 2013, 25, 289-295.	1.1	16
121	Are Prostate-Specific Antigen Changes Valid Surrogates for Survival in Hormone-Refractory Prostate Cancer? A Meta-Analysis Is Needed!. <i>Journal of Clinical Oncology</i> , 2007, 25, 5673-5674.	0.8	15
122	The impact of data errors on the outcome of randomized clinical trials. <i>Clinical Trials</i> , 2017, 14, 499-506.	0.7	15
123	Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time. <i>Biometrics</i> , 2012, 68, 248-257.	0.8	14
124	Should Dukes' B patients receive adjuvant therapy? A statistical perspective. <i>Seminars in Oncology</i> , 2001, 28, 20-24.	0.8	14
125	Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring. <i>Clinical Trials</i> , 2019, 16, 512-522.	0.7	13
126	Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1186-1191.	3.0	13

#	ARTICLE	IF	CITATIONS
127	The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 275-280.	0.5	13
128	Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author's reply. <i>Lancet Oncology</i> , 2016, 17, e176-e177.	5.1	12
129	A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. <i>Statistical Methods in Medical Research</i> , 2019, 28, 170-183.	0.7	12
130	Unbiasedness and efficiency of non-parametric and UMVUE estimators of the probabilistic index and related statistics. <i>Statistical Methods in Medical Research</i> , 2021, 30, 747-768.	0.7	12
131	Meta-analysis of randomized clinical trials in the era of individual patient data sharing. <i>International Journal of Clinical Oncology</i> , 2018, 23, 403-409.	1.0	11
132	Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2009, 14, 95-101.	1.0	10
133	Assessing Treatment Benefit in Immuno-oncology. <i>Statistics in Biosciences</i> , 2020, 12, 83-103.	0.6	10
134	The ARCAD Clinical Trials Program: An Update and Invitation. <i>Oncologist</i> , 2012, 17, 188-191.	1.9	9
135	Central statistical monitoring of investigator-led clinical trials in oncology. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1207-1214.	1.0	9
136	Re: A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2001, 93, 399-400.	3.0	7
137	Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia. <i>Trials</i> , 2011, 12, 86.	0.7	7
138	Validation of Biomarkers as Surrogates for Clinical Endpoints. <i>Drugs and the Pharmaceutical Sciences</i> , 2003, , .	0.1	7
139	Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	2.8	6
140	The Net Benefit of a treatment should take the correlation between benefits and harms into account. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 148-158.	2.4	6
141	Detection of Fraud in a Clinical Trial Using Unsupervised Statistical Monitoring. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 130-136.	0.8	6
142	Clinical Research after Drug Approval: What is Needed and What is Not. <i>Drug Information Journal</i> , 1999, 33, 627-634.	0.5	5
143	Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints. <i>Current Opinion in Oncology</i> , 2020, 32, 384-390.	1.1	5
144	Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study. <i>Statistics in Medicine</i> , 2021, 40, 553-565.	0.8	5

#	ARTICLE	IF	CITATIONS
145	A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons. <i>Biometrical Journal</i> , 2021, 63, 272-288.	0.6	4
146	Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 417-425.	1.1	3
147	Cornerstones of a well-designed phase III trial. <i>European Journal of Cancer, Supplement</i> , 2003, 1, 67-75.	2.2	3
148	Correcting the bias of the net benefit estimator due to right-censored observations. <i>Biometrical Journal</i> , 2021, 63, 893-906.	0.6	3
149	Progress in the medical treatment of advanced colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 711-716.	1.1	2
150	Comparison of the Levogyre and Dextro-Levogyre Forms of Leucovorin in a Phase III Trial of Bimonthly LV5FU2 Versus Monthly 5-Fluorouracil and High-Dose Leucovorin for Patients With Stage II and III Colon Cancer (GERCOR C96.1). <i>Clinical Colorectal Cancer</i> , 2010, 9, E5-E10.	1.0	2
151	Fraud in clinical trials: complex problem, simple solutions?. <i>International Journal of Clinical Oncology</i> , 2016, 21, 13-14.	1.0	2
152	Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3442.	1.7	2
153	Generalized Pairwise Comparisons for Prioritized Outcomes. , 2021, , 1-25.		2
154	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
155	What Does Metastasis-Free Survival Actually Mean?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1679-1680.	0.8	1
156	Counting and sampling errors: (Mis)interpretation of data from tritiated thymidine labelled human tumors. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 895-896.	0.9	0
157	E23. Statistical issues in the validation of biomarkers and surrogate endpoints. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 48-49.	2.2	0
158	Reply to R. Simon. <i>Journal of Clinical Oncology</i> , 2011, 29, 2941-2944.	0.8	0
159	Surrogate end points: when should they be used?. <i>Clinical Investigation</i> , 2013, 3, 1147-1155.	0.0	0
160	Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer. <i>Contemporary Clinical Trials</i> , 2021, 105, 106400.	0.8	0
161	Fraud in Clinical Trials. , 2020, , 1-20.		0